You still need the CAR-T therapy but Leronlimab would be an extremely useful adjunctive therapy if the patient develops CRS. The Jerusalem Post article touts “experimental “ therapy 90% cure rate for multiple myeloma…some articles from that source strike me as a bit of marketing hype…CAR-T for multiple myeloma isn’t new, I know it is used at Mass General in Boston. It is miraculous in that it can be curative, ergo a great hope. Caveat CRS and adjunctive treatment (steroids et al)…Leronlimab would be like pulling out the big guns to stop CRS cold. We’ve talked about this before on this board…this is the same dynamic with critical covid19. Heavy doses of steroids is now standard of care for that but does carry the double-edged sword of immune suppression when you need to clear the virus. Imagine a more targeted therapeutic with a mechanism of action more precisely in tune with the immunological response.

I can hardly wait for this molecule to get out there and flex its muscles.